State of care for hemophilia in pediatric patients

Pediatric Drugs

Volumn 4, Issue 3, 2002, Pages 149-157

  Santagostino, Elena ^a   Gringeri, Alessandro ^a   Mannucci, Pier M ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIFIBRINOLYTIC AGENT; ANTIINFLAMMATORY AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DESMOPRESSIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ARTHROPATHY; BLEEDING; BLEEDING TENDENCY; CHILD; CONCENTRATION RESPONSE; DISEASE SEVERITY; DRUG INFUSION; DRUG SAFETY; HEMARTHROSIS; HEMOPHILIA; HOME CARE; HUMAN; HYPONATREMIA; IMMUNOLOGICAL TOLERANCE; INFECTION RISK; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SEIZURE;

EID: 0036214098     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204030-00002     Document Type: Review

References (45)

1. Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate
2. Low risk of viral infection after administration of vapour-heated factor VIII concentrate
3. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate
4. Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate
5. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B
6. Hemophilia prophylaxis in young patients: A long-term follow-up
7. Hemophilia in the first year of life
8. GIPSI (German-Italian PUP Study on Inhibitor): Natural history of hemophilia in the first years of life
9. Accelerated schedule of hepatitis B vaccination in patients with hemophilia
10. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients
11. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders
12. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy
13. 1-Deamino-8-D-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrand's disease
14. Effect of dry-heating of coagulation factor concentrate at 80°C for 72 hours on transmission of non-A non-B hepatitis
15. Acute hepatitis A in patients with haemophilia A
16. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses
17. Human parvovirus B 19 infection in hemophiliacs first infused with two high-purity, virally attenuated, factor VIII concentrates
18. Eliminating parvovirus B 19 from blood products
19. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A -safety, efficacy, and development of inhibitors
20. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
21. Factor VIII inhibitors: Etiology, characterization, natural history and management
22. The natural history of factor VIII inhibitors in patients with hemophilia A: A national cooperative study
23. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIII immunoaffinity chromatography
24. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
25. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
26. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
27. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A
28. Nasal spray desmopressin (DDAVP) for mild hemophilia and von Willebrand disease
29. Considerations for current and future management of haemophilia and its complications
30. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs
31. Suggestions for the management of factor VIII inhibitors
32. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)
33. Adverse effects of treatment with porcine FVIII
34. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial
35. Myocardial infarction complicating activated prothrombin complex concentrate substitution in a patient with haemophilia A
36. Clinical experience with recombinant factor VIIa
37. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention
38. Acute myocardial infarction following administration of recombinant activated factor VII (Novoseven) in a patient with haemophilia A and inhibitor
39. Induced immune tolerance in factor VIII inhibitor patients
40. Disappearance of factor VIII:C antibodies in patients with hemophilia A upon frequent administration of factor VIII in intermediate or low dose
41. Immune tolerance in hemophilia. Principal results from an international registry
42. Management of hemophilia B patients with inhibitors and anaphylaxis
43. Complications of indwelling venous access lines in the pediatric hematology patient: A prospective comparison of external venous catheters and subcutaneous ports
44. Use of central venous catheters in children with severe congenital coagulopathy
45. A prospective clinical trial of implantable central venous access in children with haemophilia